** Biotech firm Aligos Therapeutics'ALGS.O shares fall 17.3% to $10.70, hit three-month low
** Company posts quarterly net loss of $13.08 per share vs loss of $5.50 per share a year earlier
** Reports cash equivalents and investments in 2024 of $56.9 million vs $135.7 million in 2023, which will provide sufficient funding of planned operations into H2 2026
** Company says it is continuing to evaluate a variety of options to fund continued development of its liver disease drug, including potential out-licensing
** As of last close, ALGS has fallen 44.3% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.